1. Pharmacological treatments for cannabis use disorder

Despite the high prevalence of CUD in Western countries (0.5% of adults in Europe) and the increasing demand for treatment, there are currently no pharmacotherapies approved by international agencies (e.g. U.S. Food and Drug Administration or European Medicines Agency). Potential pharmacological targets are very heterogeneous (e.g. antiepileptics, antipsychotics, antidepressants, cannabinoids), and target withdrawal symptoms and/or promote reduction of use or abstinence. In this session, we will review the current state of evidence regarding pharmacological treatments for CUD, while considering the background of the participants.

Non-systematic review of pharmacological treatments for CUD Critical analyses of results.

• <(li>There is no gold standard for pharmacological treatment of CUD
• Participants were offered concomitant psychological interventions
• Cannabidiol and other cannabinoids are promising compounds for relapse prevention
• Most study participants were male, and studies were performed in Western countries

Further research is required for achieving evidence-based treatment for relapse prevention in CUD. As in other substance use disorders, the role of concomitant psychotherapy should be clarified. Key targets for pharmacological treatments are worth further investigation. Unpowered clinical trials must be avoided.